SecBot SecBot
SECBOTREPLAY Home › Report › BCAX

BCAX · Three top executives at Bicara Therapeutics (CEO, President/COO, CFO)…

Bicara Therapeutics Inc. · CLUSTER filed Aug 12, 2026 at 16:19 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Aug 12, 2026 at 16:19 ET

Three top executives at Bicara Therapeutics (CEO, President/COO, CFO) executed same-day option exercises and open-market sales on August 10, 2026, totaling $1.15M in sales. This cluster follows the company's Q2 earnings report (net loss $0.82/share, in line with consensus) and the announcement of CEO Claire Mazumdar's planned departure in January 2027. The sales are likely liquidity-driven (option exercise to cover taxes and diversification) rather than a bearish signal, but the timing, one day after earnings and amid a leadership transition, warrants attention.

  • CEO Claire Mazumdar sold 10,000 shares for $279,750 on August 10, 2026, following option exercise.
  • President/COO Ryan Cohlhepp sold 18,750 shares for $524,533 on August 10, 2026, following option exercise.
  • CFO Ivan Hyep sold 12,500 shares for $349,591 on August 10, 2026, following option exercise.
  • Total open-market sales by the three executives: $1.15M, representing ~0.07% of BCAX's $1.6B market cap.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access